uniQure N.V. (NASDAQ:QURE) does about 586.79K shares in volume on a normal day but saw 1368546 shares change hands in Tuesday trading. The company now has a market cap of 1.08B USD. Its current market price is $23.00, marking an increase of 7.08% compared to the previous close of $21.48. The 52 week high reached by this stock is $30.41 whilst the lowest price level in 52 weeks is $12.52. The script in recent trading has seen the stock touch a high of $23.92 and a low of $20.81.
uniQure N.V. (QURE) has a 20-day trading average at $20.31 and the current price is -24.37% off the 52-week high compared with 83.71% distance from its 52-week low. The 50-day simple moving average of the closing price is $19.51 and its 200-day simple moving average is $18.41. If we look at the stock’s price movements over the week, volatility stands at 6.86%, which decreases to 5.79% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 64.71 to suggest the stock is neutral.
18 analysts observing the uniQure N.V. (QURE) stock have set the 12-month price targets for the company’s shares at between $24.00 and $90.00. The consensus objective for the share price is $49.31, suggesting that the stock has a potential upside of 53.36% over the period. The median price target is 55.77% away from the current levels at $52.00.
FactSet Research has provided data showing that 18 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 1 advise that it is a overweight. 16 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 17, 2022 when UBS upgraded the stock to “Buy” and issued a price target of $40. UBS initiated its price target at $40.
The current price level is 14.39%, 18.25%, and 25.10% away from its SMA20, SMA50, and SMA200 respectively, with the QURE price moving above the 50-day SMA on November 22. uniQure N.V. (QURE) stock is up 5.02% over the week and 24.53% over the past month. Its price is 10.90% year-to-date and -20.19% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$1.02 above consensus estimates by $0.14. The company’s next earnings report is expected on 03/15/2023, with forecasts estimating quarterly EPS at -$0.82 and -$3.68 for whole year. QURE’s earnings per share are forecast to shrink by -152.30% this year and 62.50% over next year. Expected sales for next quarter are $91.46 million, which analysts say will come at $25.9 million for the current fiscal year and next year at $187.29 million. In addition, estimates put the company’s current quarterly revenue at an average of $25.31 million.
To reach the target analysts have set, the stock logically needs to grow 53.36 percent from here.
Outstanding shares total 46.77M with insiders holding 7.21% of the shares and institutional holders owning 92.07% of the company’s common stock. The company has a return on investment of 44.10% and return on equity of -24.50%. The beta has a value of 0.96. Price to book ratio is 2.56 and price to sales ratio is 17.59.
According to a U.S. Securities and Exchange Commission filing, iShares Core S&P Small Cap ETF has added its position in uniQure N.V. (QURE) to 3,045,233 shares, mirroring a recent increase by 0.08%. iShares Core S&P Small Cap ETF added 2328.0 shares of uniQure N.V. common stock bringing its total worth to about $56.7 million at the end of recent close, SEC documents show. iShares Core S&P Small Cap ETF isn’t the only investment manager who changed stakes and is followed by SPDR S&P Biotech ETF, which added 13740.0 shares to end up with 2,483,209 shares worth $46.24 million. Worldwide Healthcare Trust Plc raise their holdings by 49.36% in the company over the course of the most recent quarter. It now holds a 1.76% position in uniQure N.V. thanks to 0.82 million shares amounting to $15.32 million.